Blog
RSS FeedPosted by Michael Wonder on 31 Aug 2025
FDA approval of Leqembi subcutaneous formulation charts path to combination therapies for Alzheimer's disease
29 August 2025 - Subcutaneous delivery increases accessibility and introduces potential for at home administration, following model of diabetes and ...
Posted by Michael Wonder on 18 Jan 2021
Double vaccine rollout in plan to defeat COVID-19
19 January 2021 - The nation’s top scientific advisers could recommend the rollout of a second round of immunisations to ...
Posted by Michael Wonder on 18 Jan 2021
SMC - January 2021 decisions
18 January 2021 - The SMC, which advises on newly licensed medicines for use by NHSScotland, has today published advice ...
Posted by Michael Wonder on 18 Jan 2021
HHS regulations with enduring impact on pricing and reimbursement of medical services and technologies
17 January 2021 - The Trump Administration’s grandiose healthcare plans didn’t come to fruition, like the promised repeal and replace of ...
Posted by Michael Wonder on 18 Jan 2021
Changes to Medicare Advantage and Part D will provide better coverage, more access and improved transparency for Medicare beneficiaries
15 January 2021 - Today, the CMS issued a final rule that further advances the agency’s efforts to strengthen and modernise ...
Posted by Michael Wonder on 18 Jan 2021
FDA sped progress for most of 2020's novel drugs
14 January 2021 - Most novel drugs approved by the US FDA in 2020 made their way through the approvals process ...
Posted by Michael Wonder on 18 Jan 2021
ICER issues correction to final evidence report on new therapies for bladder cancer
15 January 2021 - After correcting an input to the cost-effectiveness model, ICER’s health-benchmark price benchmark range for nadofaragene firadenovec has ...
Posted by Michael Wonder on 18 Jan 2021
Norwegian investigation of COVID-19 vaccination risks for elderly, very frail patients
17 January 2021 - In recent days the TGA has received reports of about 30 deaths in over 40,000 elderly individuals ...
Posted by Michael Wonder on 18 Jan 2021
How NZ is preparing for the biggest vaccine roll-out in history
17 January 2021 - “When will we get a vaccine for COVID-19?” It has been the question on everyone’s lips for ...
Posted by Michael Wonder on 17 Jan 2021
Billionaire Mark Cuban wants to lower drug prices with generics startup
15 January 2021 - Billionaire Mark Cuban is mad about the high cost of prescription drugs in the United States, ...
Posted by Michael Wonder on 16 Jan 2021
PBAC Public Summary Documents (rejections/deferrals/other matters) - September 2020 intracycle meeting
15 January 2021 - The Public Summary Documents (rejections/deferrals/other matters) from the September 2020 PBAC untracycle meeting are now available. ...
Posted by Michael Wonder on 16 Jan 2021
Herd immunity muddies the waters
16 January 2021 - With case numbers exceedingly low, and the nation poised to roll out the first COVID-19 immunisations ...
Posted by Michael Wonder on 16 Jan 2021
Strengthening patient outcome evidence in health technology assessment: a coproduction approach
13 January 2021 - NICE worked with patients and staff from six patient organisations to review existing health technology assessment ...
Posted by Michael Wonder on 16 Jan 2021
NICE’s approach to measuring value
5 January 2021 - Appleby asks whether COVID-19 vaccines would be considered cost effective using the NICE approach to measuring ...
Posted by Michael Wonder on 16 Jan 2021
FDA grants accelerated approval to Darzalex Faspro for newly diagnosed light chain amyloidosis
15 January 2021 - Today, the FDA granted accelerated approval to daratumumab plus hyaluronidase (Darzalex Faspro, Janssen Biotech) in combination ...
Posted by Michael Wonder on 16 Jan 2021
FDA approves fam-trastuzumab deruxtecan-nxki for HER2 positive gastric adenocarcinomas
15 January 2021 - Today, the FDA approved fam-trastuzumab deruxtecan-nxki (Enhertu, Daiichi Sankyo) for adult patients with locally advanced or ...